Glenmark Pharma soars to 52-week high on positive management commentary

Glenmark Pharma soared as management's bullish FY25 targets offset weak quarterly earnings. Despite widening losses due to impairment charges, adjusted net profit nearly tripled, driven by a stake sale in Glenmark Life Sciences.

Related Keywords

Glenmark Monroe ,Glenmark Pharma ,Us Department Of Justice Settlement ,Drug Administration ,Glenmark Life Sciences ,Glenmark Specialty ,Justice Settlement ,Glenmark Life ,